Related Experiment Video

Updated: Jul 20, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure:

N M Hawkins1, D Wang, J J V McMurray

  • 1Department of Cardiology, Stobhill Hospital, Balornock Road, Springburn, Glasgow G21 3UW, UK. nathawkins@hotmail.com

Heart (British Cardiac Society)
|September 6, 2006
PubMed

Insights

Electrocardiographic left ventricular hypertrophy (ECG LVH) is common in heart failure patients and independently predicts worse outcomes. This finding holds true across various left ventricular ejection fractions (LVEF) and treatments.

Area of Science:

  • Cardiology
  • Clinical Medicine
  • Cardiovascular Research

Background:

  • Electrocardiographic left ventricular hypertrophy (ECG LVH) is a significant predictor of cardiovascular events in hypertension.
  • Understanding its role in heart failure is crucial for risk stratification.

Purpose of the Study:

  • To assess the prevalence and prognostic impact of ECG LVH in a diverse heart failure patient population.
  • To evaluate ECG LVH in patients with preserved and reduced left ventricular ejection fraction (LVEF).

Main Methods:

  • Analysis of 7599 patients from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
  • Utilized Cox regression models to determine the relative risk (RR) associated with ECG LVH, adjusting for 31 covariates.

Main Results:

  • ECG LVH prevalence was consistent across CHARM trials (14.7%–17.1%), irrespective of hypertension history.
  • ECG LVH independently predicted poorer outcomes, with RR for primary composite outcome at 1.27 (p=0.018).
  • Increased risks observed for cardiovascular death (RR 1.50) and major cardiovascular events (RR 1.35).

Conclusions:

  • ECG LVH is prevalent in symptomatic heart failure patients regardless of LVEF.
  • ECG LVH serves as an independent predictor of adverse clinical outcomes in heart failure.
  • Candesartan demonstrated comparable efficacy in patients with and without ECG LVH.
Abstract

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...